About This Initiative
Clostridioides difficile infection (CDI) is the most common healthcare-associated infection and the most common cause of mortality in patients with gastroenteritis in the United States. Historically, approximately one in four patients suffer from recurrent CDI, which is associated with increased morbidity, mortality, healthcare costs, and decreased quality of life. . Recent updates to national guidelines place a greater emphasis on recurrence prevention. This series explores these guideline updates and their application in special patient populations, with a focus on those at high risk for recurrent CDI.
Virtual Midday Symposium (ASHP Midyear Registration is Not Required)
This 1.5-hour interprofessional educational activity examines recent data on Clostridioides difficile infection pharmacotherapy and uses a case-based approach to apply recent guideline recommendations to special patient populations, with a focus on those at high risk for recurrent CDI.
Ask the Experts Webinar
The content for this activity is based on questions and comments from participants in the first educational activity on this topic.